PPARa is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. PPARa is involved in the regulation of in vivo triglyceride levels, presumably through its effects on fatty acid and lipoprotein metabolism. Some nuclear receptors have been involved in rapid effects mediated by non-genomic mechanisms. In this paper, we report the rapid non-genomic effects of PPARa ligands on the intracellular calcium concentration ([Ca 2C ] i ), mitochondrial function, reactive oxygen species (ROS) generation, and secretion of insulin in freshly isolated mouse islets of Langerhans. The hypolipidemic fibrate PPARa agonist WY-14 643 decreased the glucose-induced calcium oscillations in intact islets. This effect was mimicked by the synthetic agonist GW7647 and the endogenous agonist oleylethanolamide. The WY-14 643 action was rapid in onset (5 min) and was still produced in the presence of protein and mRNA synthesis inhibitors, cycloheximide, and actinomycin-D. This suggests that it is independent of gene transcription. In addition, WY-14 623 impaired mitochondrial function, increased ROS formation and decreased insulin release. PPARa is present in b-cells, mainly in the cytosol and nucleus, with a small subpopulation localized in the plasma membrane. However, the presence of the PPARa ligand effects in mice bearing a disrupted Ppara gene raises the possibility that the rapid effects of the agonists in pancreatic b-cells are independent of the receptor. We conclude that PPARa agonists produce a decrease in glucose-induced [Ca 2C ] i signals and insulin secretion in b-cells through a rapid, non-genomic mechanism.
Introduction
Blood glucose is maintained within a very narrow range by the action of two main hormones: insulin and glucagon. Insulin is synthesized and secreted from pancreatic b-cells and glucagon from a-cells. Both cell types are components of the islet of Langerhans, the physiological unit of the endocrine pancreas.
Insulin is the only hormone able to reduce blood glucose levels by decreasing glucose output and increasing the rate of glucose uptake, mainly in the striatal muscle and adipocytes (Pessin & Saltiel 2000) . Type II diabetes is characterized by the impaired insulin secretion of pancreatic b-cells in response to glucose and, by insulin resistance.
The stimulus-secretion coupling process in b-cells involves the metabolism of glucose. Oxidative metabolism via the pyruvate dehydrogenase complex and the tricarboxylic acid cycle generates ATP, which triggers glucose-stimulated insulin secretion. An increase in the (ATP)/(ADP) ratio leads to the closure of the ATP-dependent potassium channels (K ATP ), responsible for the resting membrane potential. As a result, the plasma membrane depolarizes, the voltage-gated calcium channels open and thus, [Ca 2C ] i increases (Ashcroft & Rorsman 1989 , Rorsman et al. 2000 . When b-cells are within the islet of Langerhans, their glucose-induced [Ca 2C ] i signal is organized in a synchronous and homogeneous [Ca 2C ] i oscillatory pattern (Santos et al. 1991 , Valdeolmillos et al. 1993 , Nadal et al. 1999 , Fernandez & Valdeolmillos 2000 , provoking a pulsatile insulin secretion (Gilon et al. 1993 , Barbosa et al. 1996 .
Peroxisome proliferator-activated receptors (PPARs) encompass a three-member subgroup (a, g, and b/d) belonging to the nuclear hormone receptor superfamily of ligand activated transcription factors (Robinson-Rechavi et al. 2003) . PPARs, particularly PPARa and g, are regulators of lipid metabolism because they act as lipid sensors.
Therefore, PPAR ligands represent important pharmaceutical agents involved in metabolic disorders that include type II diabetes and dyslipidaemia (Gardner et al. 2005a) . PPAR ligands act classically through PPAR binding, triggering the transcription of target genes. In addition to this established mechanism of action, growing evidence points to the existence of a non-genomic effect of PPAR ligands via a PPARindependent pathway. These non-genomic actions include mitochondrial effects, rapid reactive oxygen species (ROS) formation, MAPK activation, and expression of immediate early genes, even in cell types that do not express PPAR (Pauley et al. 2002 , Gardner et al. 2003 , Perez-Ortiz et al. 2004 , Gardner et al. 2005b . These actions are similar to those described for other nuclear receptors (Migliaccio et al. 1998 , Nadal et al. 2001 , Losel et al. 2003 . The physiological dimension of PPAR ligands is reflected by their rapid induction of satiety (Rodriguez et al. 2001) , insulin-induced glucose uptake by the adipocytes (Gonzalez-Yanes et al. 2005) , and visceral analgesia (Suardiaz et al. 2007) .
PPARa exists in pancreatic b-cells and its expression is down-regulated (60-80% reduction) after being exposed to high glucose for several days (Zhou et al. 1998 , Roduit et al. 2000 . Here, we have shown that PPARa agonists rapidly regulate glucose-induced [Ca 2C ] i in a non-genomic manner. In addition, the agonist WY-14 643 acts on mitochondrial function, activates ROS, and decreases insulin release. Moreover, the WY-14 463-induced regulation of [Ca 2C ] i signals is still produced in islets from mice with a disrupted Ppara gene, suggesting that the non-genomic action of PPARa agonists in pancreatic b-cell signaling may be independent of the receptor.
Materials and Methods

Drugs
The PPARa ligands WY-14 643, oleoylethanolamide, and GW-7647 were purchased from TOCRIS (Biogen, Barcelona, Spain). Lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC) and the remaining reactive and salts were purchased from Sigma Chemicals.
Islet and cell preparation
Swiss albino OF1 male mice (8-10 weeks old) were used and humanely killed by cervical dislocation. An internal animal care and use committee reviewed and approved the method used in strict adherence to the European Community Council Directive 86/609/EEC regulating animal research. Pancreatic islets of Langerhans were isolated by collagenase digestion as previously described (Nadal et al. 1998) and loaded with 5 mM Fura-2 AM for at least 1 h at room temperature. Loaded islets were kept in a medium containing (mM): 115 NaCl, 10 NaHCO 3 , 5 KCl, 1 . Recording intracellular calcium, NADH, and mitochondrial membrane potential (DJm) Calcium records in whole islets of Langerhans were obtained by imaging intracellular calcium under an inverted epifluorescence microscope (Zeiss, Jena, Germany, Axiovert 200). Images were acquired approximately every 3 s with an extended Hamamatsu Digital Camera C4742-95 (Hamamatsu Photonics, Barcelona, Spain) using a dual filter wheel (Sutter Instrument Co., Nevato, CA, USA) equipped with 340 and 380 nm, 10 nm band-pass filters (Omega Optics, Madrid, Spain). Data were acquired using ORCA software from Hamamatsu (Hamamatsu Photonics). Fluorescence changes are expressed as the ratio of fluorescence at 340 and 380 nm (F 340 /F 380 ). Results were plotted using commercially available software (Sigmaplot, Jandel Scientific). The amplitude of the [Ca 2C ] i oscillations was calculated for a period of 10-15 min before stimuli application (control). It was then measured for 10 min (from 15 to 25 min) while stimuli were being applied. The area under the traces was measured using SigmaPlot for a period of 15 min after the application of stimulatory glucose concentration.
NADH autofluorescence and DJm were monitored using the same imaging system described in the paragraph above. NADH fluorescence was excited with a 365 nm band-pass filter, while emission was filtered at 445G25 nm (Pertusa et al. 2002 , Quesada et al. 2006 ). An image was acquired every 60 s. DJm was measured using rhodamine-123 (Molecular Probes, Eugene, OR, USA). Islets were loaded with 10 mg/ml rhodamine-123 for 20 min and imaged using conventional fluorescein filters (Pertusa et al. 2002 , Ravnskjaer et al. 2005 ). An image was acquired every 90 s.
Insulin secretion
After 1 h recovery in the incubator in the isolation medium, groups of five islets were incubated for 1 h in 0 . 4 ml of a buffer solution containing 120 mM NaCl, 25 mM NaHCO 3 , 5 mM KCl, 2 . 5 mM CaCl 2 , and 1 . 1 mM MgCl 2 (pH 7 . 35) in the presence of different stimuli. After 1 h, 0 . 1 ml of the previous buffer solution with 5% BSA was added and gently shaken for homogenization. Then, the medium was immediately collected and insulin was measured in duplicate by RIA using a Coat-a-count (DPC, Los Angeles, CA, USA). Total protein amount was determined by the Bradford method.
ROS measurement
Whole islets of Langerhans were incubated in a modified ringer solution with 4 mM 6-carboxy-2 0 ,7 0 -dichlorodihydrofluorescein diacetate (DHCF), di(acetoxymethyl ester), C2938, Molecular Probes) for 30 min at 37 8C. After this, the islets were transferred to a recording chamber and ROS were imaged using a Zeiss Pascal 5 confocal microscope at 36 8C with 488 nm excitation and 520 nm emission. A concentration of 100 mM H 2 O 2 was used as a control at the end of each experiment. Only those islets that responded to H 2 O 2 with a significant increase in fluorescence were taken into consideration for the experiment.
Quantitative real-time PCR
To obtain a measurement of PPARa expression in several representative tissues from mice, a relative quantification assay of Ppara versus Histone (housekeeping gene) mRNA was performed. For this purpose, real-time quantitative PCR technology was used. Total RNA isolation from snap frozen tissue samples was obtained using Trizol reagent (Gibco BRL Life Technologies) according to the manufacturer's instructions. All RNA samples showed A260/280 ratios between 1 . 8 and 2 . 1. Total RNA from each sample and random hexamers were immediately used to generate first strand cDNA, by using transcriptor reverse transcriptase (Roche Applied Science) according to the manufacturer's instructions. Negative controls included RT reactions omitting reverse transcriptase. The obtained cDNAs were used as the template for real-time quantitative PCR, which was performed using the Opticon Engine System (MJ Research) with the SYBR Green I detection format and using the QuantiTect SYBR Green PCR kit (Qiagen GmbH, Germany). Primers for PCR were designed based on NCBI database sequences of mouse Ppara (accession NM_011144.2) and Histone (accession NM_175660.1) mRNAs and tested to ensure the amplification of single discrete bands with no primer dimers. Primer sequences were as follows: Ppara forward, 5 0 -TgCTgTCCTCCTTgATgAAC-3 0 ; Ppara reverse, 5 0 -gCTTAAgCACgTgCACAATC-3 0 (270 bp product); Histone forward, 5 0 -CTgTgCTggAgTACCTgACg-3 0 ; and Histone reverse, 5 0 -ATTACTTCCCCTTggCCTTg-3 0 (234 bp product). They were obtained from Proligo France SAS (Paris, France). The quantification was carried out based on standard curves run at the same time as samples. Ppara and Histone standards were generated by PCR amplification from control samples. The PCR product was run in a 1% agarose gel electrophoresis to check the fragment size and the absence of other contaminant fragments, quantified by 260 nm absorbance, and serially diluted to 10 K6 pg/ml. Several 10-fold dilutions (10 K1 -10 K6 ) were checked for optimal cycling using the Opticon Engine System and 5 were selected to run the standard curve. Each reaction was run in duplicate and contained 3 ml cDNA template, 5 mM Cl 2 Mg, and 0 . 2-0 . 4 mM primers in a final reaction volume of 20 ml. The cycling parameters were 95 8C for 15 min to activate DNA polymerase, followed by 30-40 cycles of 95 8C for 15 s, annealing temperature for 30 s (Ppara: 56 8C, Histone: 64 8C) and a final extension step of 72 8C for 30 s in which fluorescence was acquired. Melting curve analysis was performed to ensure that only a single product was amplified. Once the absolute values for both Ppara and Histone were obtained from each sample, the Ppara/Histone ratio was calculated.
Immunocytochemistry Islets isolated as previously described were fixed with Bouin's solution for 5 min and washed with PBS. Then, they were dehydrated with 30, 50, and 70% ethanol, for 3 min each, and washed with PBS. After this, the islets were treated with 0 . 5% Triton X-100 for 15 min and then washed with PBS. The non-specific staining was blocked with PBS supplemented with 0 . 1% Triton X-100 and 5% serum from the same host as the secondary antibodies used. After the islets had been incubated for 1 h at room temperature, primary antibodies were added to the blocking solution. These were anti-PPARa (1:250, PA1-822A, ABR; 1:100, H98, Santa Cruz) and antiinsulin (1:200, Sigma). The islets were incubated overnight with the primary antibodies at 4 8C. Secondary antibodies (Alexa Fluor Molecular Probes) were used at 1:1000 in PBS plus 1% serum from the same host as the secondary antibodies, for 1 h at room temperature. To stain mitochondria, live islets were previously incubated with 500 nM Mitotracker Red CMXRos (Molecular Probes) for 30 min, then washed with PBS and fixed as described. To stain the plasma membrane, 1 mg/ml wheat germ agglutinin-tetramethylrhodamine was used (WGA, Molecular Probes, W849) and added at the same time as the primary antibody. A confocal Zeiss Pascal 5 microscope and a Zeiss 40! objective (numerical apertureZ 1 . 3) were used to obtain images for quantification. The images were analyzed using LSM Zeiss software (Zeiss).
Cell viability assay
Islets were dispersed into single cells with trypsin. Cells were then centrifuged and resuspended in medium containing (mM): 115 NaCl, 10 NaHCO 3 , 5 KCl, 1 . 1 MgCl 2 , 1 . 2 Figure 1 PPARa is present in mouse islets of Langerhans. Quantification by real-time PCR of mRNA levels in different tissues from mice. Values are the mean of two independent experiments with 1000 islets each, from 13 mice. NaH 2 PO 4 , 2 . 5 CaCl 2 , and 25 HEPES; plus 1% albumin; and 5 mM D-glucose (pH 7 . 35). They were plated on 24 mm glass covers previously coated with poly-L-lysine. The cells were left to attach for 1 h at 37 8C and the medium was replaced with fresh medium plus the stimuli for 90 min. After this, the cells were washed twice with PBS and incubated with 2 mM calcein and 4 mM ethidium homodimer 1 (Live/Dead Viability/Cytotoxicity Kit, Molecular Probes) at room temperature for 45 min whilst being gently shaken. The covers were taken under a fluorescence microscope and live cells were counted as positive for calcein (green cells), while dead cells were positive for ethidium homodimer 1 (red nuclei).
Ppara gene disrupted mice
Mice homozygous for the Ppara tm1Gonz targeted mutation were obtained from the Jackson Laboratories (Bar Harbor, ME, USA). They were generated by Lee et al. by inserting a 1 . 14 kb neomycin resistance gene into the exon 8 that encodes the ligand-binding domain in the opposite transcriptional direction of the mouse Ppara gene. Results showed that the northern blot analysis did not detect a transcript of wild type size on the RNA derived from the liver of homozygous mice, although a larger abnormal transcript was detected (Lee et al. 1995) .
Statistical analysis
Data are expressed as meanGS.E.M. Comparisons were made using a two-tailed Student's t-test, unless stated otherwise.
A probability level of !0 . 05 was considered statistically significant.
Results
PPARa expression and location within intact islets of Langerhans
Quantitative real-time PCR confirmed that Ppara is expressed in isolated islets of Langerhans (Fig. 1) . Figure 2A -C shows that PPARa is expressed in insulin containing b-cells and that it is located in the nucleus, as well as in the cytosol ] i in b-cells within intact islets of Langerhans, isolated islets were loaded with the fluorescent calcium sensitive dye Fura-2. Changes in the ratio F 340 /F 380 were monitored using a conventional imaging system. All the different cell types are present within an islet; however, the average signal of the whole islet corresponds to the b-cell type (Valdeolmillos et al. 1993 , Nadal et al. 1999 . The [Ca 2C ] i oscillations induced by a stimulatory glucose concentration (11 mM) were inhibited by WY-14 643 in 47% of the islets tested ( Fig. 3A and C) , while a change in the glucose-induced [Ca 2C ] i oscillatory pattern was manifested in 20% of the islets (Fig. 3B) . In these cells, the oscillations became wider and less frequent. This inhibitory effect of WY-14 643 was dosedependent ( Supplementary Figures 2A and 3 , see Supplementary data in the online version of the Journal of Endocrinology at http://joe.endocrinology-journals.org/ content/vol200/issue2/). The silencing action of WY was not due to a damaging effect of the fibrate, since islets were still able to respond to stimulation with high K C concentration (Fig. 3D) .
When the islets were pre-incubated for 30 min with 5 mM WY-14 643, as well as during the experiment, the glucoseinduced [Ca 2C ] i response was partially inhibited to both 7 and 11 mM glucose. This is manifested as a decrease in the global Ca 2C amount entering into the islet upon stimulation, measured as the area under the traces (Fig. 4A-C) . However, when the islets were exposed to 16 mM glucose, WY was unable to have an effect (Fig. 4C) . The basal [Ca 2C ] i did not change after the 30 min incubation with WY (data not shown). Additionally, when measured the peak size of the [Ca 2C ] i transient in response to 11 mM glucose (peak size, measured as the difference between the calcium level at 3 mM glucose just before the medium was changed and the maximum amplitude of the first calcium transient in response to high glucose concentration), the PPARa agonist was able to decrease such response in 28% (Fig. 4D) . Again, WY had no effect in 16 mM glucose (data not shown).
When the same kind of experiment was performed but stimulating the b-cells with 25 mM K Insulin secretion is a pulsatile phenomenon that follows the oscillatory [Ca 2C ] i pattern (Barbosa et al. 1996) . The experiment shown in Fig. 4E was performed to evaluate the ] i oscillations in the presence of 11 mM glucose in 47% of the tested islets (7 out of the 15 islets).
(B) 0 . 5 mM WY-14 643 modified glucose-induced [Ca 2C ] i oscillations in 20% of the tested islets (3 out of the 15 islets), in 27% of the islets WY-14 643 had no effect. (C) Mean amplitude (DF 340 /F 380 ) in percentage of [Ca 2C ] i oscillations during a period of 5-10 min prior stimuli (control condition in high glucose) and 5-10 min after stimuli application in experiments of the type shown in A. (D) Islets were able to respond to 30 mM K C after the application of 5 mM WY-14 643 (nZ3 islets).
rapid effect of WY-14 643 on insulin secretion. The increase in insulin secretion produced by 11 mM glucose was blocked by the PPARa agonist. The action of WY-14 643 on [Ca 2C ] i was imitated by the synthetic PPARa agonist GW7647, which abolished glucoseinduced [Ca 2C ] i oscillations in 87% of the islets tested ( Fig. 5A and B) . However, the endogenous agonist oleylethanolamide (OEA; Fu et al. 2003 ) had a double effect, on the one hand it decreased the amplitude of glucoseinduced [Ca 2C ] i oscillations in 56% (Fig. 5C and D) of the islets while, on the other hand, it increased glucose-induced [Ca 2C ] i oscillations in 28% of the islets (Fig. 5E ). The latter is presumably due to its action through other receptors, such as GPR119 (Overton et al. 2006 , Madiraju & Poitout 2007 , since the GPR119 agonists LPC (Fig. 5F ) and LPA (data not shown) also increased [Ca 2C ] i oscillatory frequency. As well as for WY-14 643, the effect of the two PPARa agonists was dose-dependent ( Supplementary Figures 2 and 3) .
Although experiments shown in Figs 3D and 4C, and Supplementary Figure 4 point to the fact that WY-14 643 action is not due to a toxic effect, we sought to perform a viability test to further demonstrate this. We incubated isolated cells from islets for 90 min in the presence of vehicle, 5 mM WY-14 643 or 1 mM GW7647. As shown in Supplementary conditions. As a positive control to obtain maximal cell death, we used 25% DMSO.
The action of WY-14 643 on glucose-induced [Ca 2C ] i oscillations is through a non-genomic mechanism
When islets were incubated for 4 h in the presence of cycloheximide, a potent inhibitor of protein synthesis, the effect of WY-14 643 on intracellular calcium oscillations was unchanged ( Fig. 6A and C) . The pretreatment of the islets with actinomycin-D, an inhibitor of RNA synthesis, for at least 3 h, did not prevent the effect of WY-14 643 on [Ca 2C ] i ( Fig. 6B and C) . We obtained the same results when using OEA instead (Supplementary Figure 6 , see Supplementary data in the online version of the Journal of Endocrinology at http://joe.endocrinology-journals.org/content/vol200/ issue2/). These results, together with the rapid onset of the response, strongly suggest the existence of a non-genomic effect of the PPARa agonists.
WY-14 643 impairs the mitochondrial function and rapidly activates ROS
The mitochondrial function is essential for an adequate stimulus-secretion coupling in b-cells. It is known that mitochondrial impairment rapidly produces energy depletion and disrupts intracellular Ca 2C homeostasis (Freeman et al. 2006) . Since it has been shown that PPAR ligands can impair mitochondrial oxidative metabolism (Perez-Ortiz et al. 2004 , Scatena et al. 2007 , we decided to analyze the mitochondrial redox state as well as the electrochemical gradient by monitoring NADH fluorescence and mitochondrial membrane potential (DJm) respectively. Glucose metabolism activates the tricarboxylic acid (TCA) cycle, producing CO 2 and the nucleotide carriers, which reduce the power of NADH, and FADH 2 , which function as sources of electron transfer in the oxidative phosphorylation reactions that mediate ATP production (Quesada et al. 2006 , Newsholme et al. 2007 ). As we observe in Fig. 7A , the elevation of glucose to 8 mM induced an increase in NADH autofluorescence. Application of WY-14 643 further enhanced this signal. This effect was also reproduced by GW7647 (Fig. 7B) . It has been reported that PPAR ligands can inhibit electron transport, particularly at the level of NADH oxidation (Scatena et al. 2004) . Our observations also point to a similar action of WY-14 643. Blockade of the electron transport can decrease the re-oxidation of the NADH molecules generated by the TCA cycle, producing an accumulation of the reduced forms and thus, an increase in NADH fluorescence (Quesada et al. 2006) . This is the case of the inhibitor cyanide (CN; Fig. 7A and B). Given that mitochondrial ATP synthesis is largely dependent on DJm (Newsholme et al. 2007) , we also explored this parameter. The change in glucose concentrations from 3 to 8 mM produced the characteristic hyperpolarization of DJm (Pertusa et al. 2002) , which corresponds to a decrease in rhodamine-123 fluorescence (Fig. 7C) . Interestingly, the application of WY-14 643 induced a progressive loss of DJm, thus indicating an uncoupling effect on mitochondrial function. These findings are in agreement with previous reports showing similar effects with PPAR ligands (Perez-Ortiz et al. 2004) . Finally, because mitochondrial inhibitors can elevate the steady-state levels of ROS (Perez-Ortiz et al. 2004), we also examined ROS production in the presence of WY-14 643. The dye DHCF was used to measure ROS production in whole islets (Fig. 7D) . When the islets were exposed to 8 mM glucose, ROS production did not vary. However, the addition of WY-14 643 produced a dramatic rise in ROS production in 50% of the tested islets ( Fig. 7E and F) . Similar results have been found in other cellular systems (Rose et al. 1999 , Perez-Ortiz et al. 2004 . Therefore, the analysis of the redox state, DJm and ROS production indicate that WY-14 643 affects mitochondrial function, in agreement with previous studies about the effect of PPARa agonists (Rose et al. 1999 , Perez-Ortiz et al. 2004 , Scatena et al. 2004 ).
Rapid WY-14 643 effect on [Ca 2C ] i in Ppara gene disrupted mice
In order to demonstrate whether PPARa mediated the rapid action of WY-14 643, we sought to perform Ca 2C imaging experiments in islets of Langerhans from wild type (WT) and Ppara gene disrupted mice. In islets obtained from WT mice, WY-14 643 completely abolished glucose-induced [Ca 2C ] i oscillations ( Fig. 8A and B) . Remarkably, when islets from Ppara gene disrupted mice were used, the same inhibition of [Ca 2C ] i signals was obtained by applying WY-14 643 ( Fig. 8A  and B ). This result indicates that the rapid, non-genomic action of the PPARa agonist did not require the full-length Ppara.
Discussion
This report demonstrates that the PPARa agonist WY-14 643 rapidly regulates glucose-induced [Ca 2C ] i oscillations and insulin secretion. The rapid onset of the response indicates that it is a non-genomic action. This is further confirmed by the absence of effect of the mRNA synthesis inhibitor actinomycin-D, and the protein synthesis inhibitor cycloheximide. [Ca 2C ] i signals were affected in this manner not exclusively by WY-14 643, since other synthetic and endogenous PPARa agonists, such as GW7647 and OEA, produced the same action. Regarding the mechanism for the action of the PPARa ligands, we show here that they also affect the intracellular NADH concentration, the mitochondrial membrane potential, and ROS production.
Reports have shown that all members of the PPAR family are expressed in pancreatic b-cells (Zhou et al. 1998 ). However, the role of PPARa in regulating GSIS is still unclear. Some studies point to a significant reduction in GSIS. Both the ectopic PPARa expression as well as the application of the PPARa agonist clofibrate led to the conclusion that the PPARa activity could cause b-cell dysfunction, possibly through an induction of UCP2 (Tordjman et al. 2002) . Other authors showed that an acute over-expression of PPARa and RXR potentiates GSIS in INS1E cells and rat islets, although the PPARa agonist WY-14 643 diminishes insulin release in these islets (Ravnskjaer et al. 2005) . We have demonstrated here that GSIS is diminished by PPARa agonists. However, WY-14 643 was unable to affect intracellular calcium responses at 16 mM glucose or higher levels. At these concentrations, b-cells are stimulated close to the maximal response, and thus, WY-14 643 probably may not counteract the glucose effect.
Rapid non-genomic actions of PPARa ligands have been described in several cell systems. For instance, it has been reported that PPARa agonists rapidly induce MAP kinases activation (Rokos & Ledwith 1997 , Gardner et al. 2005b independently of PPARa (Gardner et al. 2003) . In addition, PPARa ligands have been found to induce expression of immediate early genes in cell lines that do not express this receptor (Pauley et al. 2002) . We have shown here that the PPARa agonist WY-14 643 modifies [Ca 2C ] i signals in islets from wild type as well as from Ppara gene disrupted mice. These mice were designed with a 1 kb fragment inserted in the last exon of the gene (exon 8), the one encoding the domain that enables the protein to act as a transcription factor. Therefore, the mRNA might still be present, although 1 kb longer, and therefore a disrupted protein would be synthesized. This protein, although unable to act as a transcription factor, may still be able to have other functions, as it may be to inhibit insulin secretion in isolated islets of Langerhans through a non-genomic mechanism. The inhibitory effect of the PPARa agonist in mice with the Ppara gene disrupted together with the rapid onset of the effect after applying WY-14 643 and the absence of inhibition by actinomycin D and cycloheximide, strongly suggests that the PPARa transcriptional activity in the regulation of [Ca 2C ] i signals is not necessary. Therefore, these data provide further evidence supporting the existence of rapid non-genomic physiological effects of PPARa ligands.
Recent studies provide further support to the physiologically relevant rapid actions of these compounds. Thus, OEA modulates glucose transport in adipocytes through a non-genomic, extracellular-regulated kinases-mediated mechanism (Gonzalez-Yanes et al. 2005) . Both OEA and WY-14 643 induce rapid visceral analgesia that is also present in Ppara gene disrupted mice (Suardiaz et al. 2007 ). However, in other models, such as satiety, the PPARa receptor independence was not fully demonstrated (Fu et al. 2003) , indicating a potential contribution of the PPARa receptor to the rapid non-genomic satiety induced by PPARa receptor ligands. Further research is needed to identify the mechanism of action of these ligands. Dual genomic/non-genomic effects have been observed in several ligand-activated transcription factors (Nadal et al. 2001 , Naranjo & Mellstrom 2007 . Whether PPARa receptors display this dual profile or not, remains to be determined.
The stimulus-secretion coupling in b-cells depends on mitochondrial activation (Detimary et al. 1994 , Quesada et al. 2006 . PPARa agonists have been shown to rapidly alter mitochondrial metabolism and to increase ROS (Rose et al. 1999 , Perez-Ortiz et al. 2004 , Scatena et al. 2004 , Gardner et al. 2005a ). In agreement with these studies, we show here that WY-14 643 can induce alterations in the mitochondrial function at multiple levels: redox state, DJm, and ROS concentrations. The changes observed strongly indicate that WY-14 643 impairs the mitochondrial function. Since multiple mitochondrial processes such as ATP synthesis and Ca 2C uptake depend on mitochondrial electrochemical gradients, the loss of DJm affect these functions (Newsholme et al. 2007 , Quesada et al. 2008 . Moreover, it has been demonstrated in b-cells that ROS can decrease ATP synthesis through activation of UCP2 (Krauss et al. 2003 , Newsholme et al. 2007 . Interestingly, PPARa activation can induce UCP2 expression and decrease insulin secretion in a b-cell line (Tordjman et al. 2002) . In addition to mitochondrial effects, ROS can also activate stress-sensitive intracellular signaling pathways, as well as several kinases, that can affect glucose-induced signaling and insulin secretion (Newsholme et al. 2007) . Therefore, multiple processes derived from the altered mitochondrial function observed here with PPARa agonists could contribute to the decrease in glucose-induced [Ca 2C ] i oscillations, as well as in glucose-stimulated insulin secretion (GSIS; Freeman et al. 2006) .
Taken altogether, and considering the physiological relevance of OEA as a modulator of energy and metabolism, the present results support the existence of rapid modulatory effects of PPARa receptor ligands on glucose-stimulated insulin secretion, through the modulation of glucose-induced [Ca 2C ] i oscillations.
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